Bullous Keratopathy Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Trefoil Therapeutics, Emmecell, Cellusion

DelveInsight's "Bullous Keratopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bullous Keratopathy, historical and forecasted epidemiology as well as the Bullous Keratopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Discover which therapies are expected to grab the Bullous Keratopathy Market Share @ Bullous Keratopathy Market Outlook- https://www.delveinsight.com/sample-request/bullous-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Bullous Keratopathy Market Report
• According to DelveInsight's epidemiology model, the total number of diagnosed prevalent cases of bullous keratopathy was approximately 192 thousand among the 7MM in 2023. This number is expected to increase during the forecast period (2024-2034), driven by an aging population and an increased number of ocular surgeries.
• In the 7MM, the US accounted for approximately 41% of total diagnosed prevalent cases of bullous keratopathy while EU4 and the UK accounted for nearly 50% of cases and Japan accounted for approximately 9% of cases in 2023.
• In 2023, the US accounted for the highest number of diagnosed prevalent cases of bullous keratopathy among the 7MM, with approximately 79 thousand cases.
• Among the EU4 and the UK, Germany had the highest number of diagnosed prevalent cases of bullous keratopathy, with approximately 26 thousand cases in 2023, followed by France with nearly 22 thousand cases. On the other hand, Spain had the lowest number of cases, with approximately 14 thousand.
• Japan accounted for approximately 18 thousand diagnosed prevalent cases of bullous keratopathy in 2023 which is expected to change during the forecast period.
• Among the gender-specific diagnosed prevalent cases of bullous keratopathy, there were approximately 30 thousand male and 48 thousand female cases in the US in 2023.
• In the UK, there were approximately 39% male and 61% female cases of bullous keratopathy in 2023.
• In 2023, Japan accounted for approximately 7 thousand male and 10 thousand female cases of bullous keratopathy, which is expected to change during the forecast period.
• The leading Bullous Keratopathy Companies such as Trefoil Therapeutics, Emmecell, Cellusion and others.
• Promising Bullous Keratopathy Pipeline Therapies such as VYZNOVA (neltependocel), EO2002, TTHX1114 (NM141), EO2002, CLS001, Fluorometholone, and others.

Stay ahead in the Bullous Keratopathy Therapeutics Market with DelveInsight's Strategic Report @ Bullous Keratopathy Therapeutics Market- https://www.delveinsight.com/sample-request/bullous-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bullous Keratopathy Epidemiology Segmentation in the 7MM
• Total Cases of Major Etiologies of Bullous Keratopathy
• Total Cases of Bullous Keratopathy in Major Etiologies
• Total Diagnosed Prevalent Cases of Bullous Keratopathy
• Gender-specific Diagnosed Prevalent Cases of Bullous Keratopathy
• Total Cases of Bullous Keratopathy in Corneal Transplant/Keratoplasty

Download the report to understand which factors are driving Bullous Keratopathy Epidemiology trends @ Bullous Keratopathy Prevalence-https://www.delveinsight.com/sample-request/bullous-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bullous Keratopathy Marketed Drugs
• VYZNOVA (neltependocel): Aurion Biotechnologies
VYZNOVA, developed by Aurion Biotechnologies, is a cell therapy indicated for treating bullous keratopathy of the cornea in Japan. VYZNOVA consists of allogeneic human corneal endothelial cells, referred to as "neltependocel", and Y-27632, a small molecule drug that inhibits Rho-associated, coiled-coil containing protein kinase. This combination facilitates the regeneration of fully differentiated corneal endothelial cells (CECs) outside the body. Donor corneal cells undergo a proprietary, multi-step process to create off-the-shelf allogeneic CECs. These cells are injected into the eye, where they form a healthy mono-layer and reduce corneal edema by removing excess fluid.

Bullous Keratopathy Emerging Drugs
• TTHX1114 (NM141): Trefoil Therapeutics
TTHX1114 (NM141) is an engineered form of fibroblast growth factor-1 protein (FGF-1). The native FGF-1 is a potent stimulator of cell proliferation and migration and has cell-protective properties. The compound uniquely activates all seven forms of the FGF receptor, contributing to its potency; however, the naturally occurring FGF-1 molecule has an extremely short half-life. The engineered FGF-1, TTHX1114, is designed to increase the half-life of the FGF-1 molecule and stimulate the proliferation and migration of corneal endothelial cells.

• EO2002: Emmecell
EO2002 is a first-in-class, non-surgical, magnetic cell-based therapy that can modify disease, developed through an exclusive magnetic cell delivery (MCD) nanoparticle platform. The MCD platform facilitates the delivery, retention, and integration of cell therapies by leveraging magnetic nanoparticles to effectively localize and integrate cell therapies to the appropriate target tissue.

• CLS001: Cellusion
CLS001 is a cell therapy product developed using an induced pluripotent stem (iPS)-derived corneal endothelial cell substitute (CECSi) with excellent proliferative properties for corneal endothelial regeneration. CECSi cells have considerable potential as an effective treatment for bullous keratopathy. When a suspension of the cells is injected into the eye with a syringe and adheres to the cornea, it restores the normal thickness and transparency of the cornea. Further, the manufacturing technology directly differentiates iPS cells into corneal endothelial replacement cells without intermediates, ensuring stable cell quality and enabling cells to be mass-produced quickly.

To learn more about Bullous Keratopathy treatment guidelines, visit @ Bullous Keratopathy Treatment Market Landscape-https://www.delveinsight.com/sample-request/bullous-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bullous Keratopathy Companies
Trefoil Therapeutics, Emmecell, Cellusion and others.

Bullous Keratopathy Treatment Market Landscape
The Bullous Keratopathy treatment market landscape involves both pharmacological and surgical therapies. Medicinal interventions such as cell therapy, hypertonic saline drops and ointment (sodium chloride 5%), antibiotics, anti-inflammatories, antiglaucoma, lubricating drops, and other medications are used for symptomatic relief. However, medical management is only favorable in the early stages of the disease, and when it fails, surgery is considered.

Bullous Keratopathy Market Outlook
Bullous keratopathy is characterized by the presence of fluid-filled blisters (bullae) on the cornea. It is primarily caused by dysfunction or damage to the corneal endothelium, a single layer of cells on the inner surface of the cornea responsible for maintaining corneal transparency and preventing corneal edema. Corneal damage can occur due to various conditions such as Fuchs' endothelial dystrophy, corneal surgeries like cataracts and glaucoma, and severe trauma or injury to the cornea.

Learn more about the FDA-approved drugs for Bullous Keratopathy @ Drugs for Bullous Keratopathy Treatment- https://www.delveinsight.com/sample-request/bullous-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Bullous Keratopathy Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Bullous Keratopathy Companies- Trefoil Therapeutics, Emmecell, Cellusion and others.
• Bullous Keratopathy Pipeline Therapies- VYZNOVA (neltependocel), EO2002, TTHX1114 (NM141), EO2002, CLS001, Fluorometholone, and others.
• Bullous Keratopathy Market Dynamics: Bullous Keratopathy market drivers and Bullous Keratopathy market barriers
• Bullous Keratopathy Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bullous Keratopathy Unmet Needs, KOL's views, Analyst's views, Bullous Keratopathy Market Access and Reimbursement

Table of Content
1. Key Insights
2. Bullous Keratopathy Market Report Introduction
3. Bullous Keratopathy Market Overview at a Glance
4. Methodology of Bullous Keratopathy Epidemiology and Market
5. Executive Summary of Bullous Keratopathy
6. Key Events
7. Bullous Keratopathy Market Disease Background and Overview
8. Patient Journey
9. Bullous Keratopathy Epidemiology and Patient Population
10. Bullous Keratopathy Marketed Drugs
11. Bullous Keratopathy Emerging Drugs
12. Bullous keratopathy: Market Analysis
13. Key Opinion Leaders' Views
14. Bullous Keratopathy SWOT
15. Bullous Keratopathy Unmet Needs
16. Bullous Keratopathy Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Psoriasis Vulgaris Market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Immune Checkpoints Activators Market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Diabetic Wound Market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Overactive Bladder Syndrome Market- https://www.delveinsight.com/report-store/underactive-bladder-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.